Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 6/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.35 |
| ▸ | MINK1 | Q8N4C8 | 3/20 | 0.35 |
| ▸ | TNIK | Q9UKE5 | 3/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.31 |
| ▸ | CDK4 | P11802 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31282190 | 1.00 | KMO (0.38) | KMOMAP4K4MINK1TNIKIDO1 | |
| SCHEMBL12537997 | 0.75 | KMO (0.46) | KMOMAP4K4IDO1MAPTKDM4E | |
| SCHEMBL12537708 | 0.74 | TRPV3 (0.40) | KMOKDM4EALDH1A1TRPV3 | |
| SCHEMBL7609085 | 0.74 | ERN1 (0.38) | KMOMAPTKDM4EALDH1A1RAB9A | |
| SCHEMBL12538500 | 0.74 | TRPV3 (0.43) | KMOMAPTKDM4EALDH1A1TRPV3 | |
| SCHEMBL12538423 | 0.74 | KMO (0.44) | KMOMAP4K4IDO1TRPV3 | |
| SCHEMBL12538116 | 0.74 | RAB9A (0.40) | MAPTKDM4EALDH1A1RAB9ATRPV3 | |
| SCHEMBL13387932 | 0.72 | ERN1 (0.47) | — | |
| SCHEMBL19471673 | 0.71 | JAK2 (0.40) | KMOIDO1 | |
| SCHEMBL12539005 | 0.71 | TRPV3 (0.43) | KMOTRPV3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282747-A1 | METHODS AND COMPOUNDS USEFUL IN THE SYNTHESIS OF AN AAK1 INHIBITOR | LEXICON PHARMACEUTICALS, INC. (US) | 2025-09-11 | — | — | US | claimed |
| WO-2023167806-A1 | METHODS AND COMPOUNDS USEFUL IN THE SYTHESIS OF AN AAK1 INHIBITOR | LEXICON PHARMACEUTICALS, INC. (US) | 2023-09-07 | — | — | WO | claimed |
| US-20250282747-A1 | METHODS AND COMPOUNDS USEFUL IN THE SYNTHESIS OF AN AAK1 INHIBITOR | LEXICON PHARMACEUTICALS, INC. (US) | 2025-09-11 | — | — | US | disclosed |
| US-12344596-B2 | Solid forms of (S)-1-((2′,6-bis(difluoromethyl)-[2,4′-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine and salts thereof | LEXICON PHARMACEUTICALS, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| US-12312325-B2 | Methods and compounds useful in the synthesis of an AAK1 inhibitor | LEXICON PHARMACEUTICALS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20230357181-A1 | METHODS AND COMPOUNDS USEFUL IN THE SYTHESIS OF AN AAK1 INHIBITOR | LEXICON PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357181-A1 | METHODS AND COMPOUNDS USEFUL IN THE SYTHESIS OF AN AAK1 INHIBITOR | LEXICON PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357181-A1 | METHODS AND COMPOUNDS USEFUL IN THE SYTHESIS OF AN AAK1 INHIBITOR | LEXICON PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357182-A1 | SOLID FORMS OF (S)-1-((2',6-BIS(DIFLUOROMETHYL)-[2,4'-BIPYRIDIN]-5-YL)OXY)-2,4-DIMETHYLPENTAN-2-AMINE AND SALTS THEREOF | LEXICON PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357182-A1 | SOLID FORMS OF (S)-1-((2',6-BIS(DIFLUOROMETHYL)-[2,4'-BIPYRIDIN]-5-YL)OXY)-2,4-DIMETHYLPENTAN-2-AMINE AND SALTS THEREOF | LEXICON PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357182-A1 | SOLID FORMS OF (S)-1-((2',6-BIS(DIFLUOROMETHYL)-[2,4'-BIPYRIDIN]-5-YL)OXY)-2,4-DIMETHYLPENTAN-2-AMINE AND SALTS THEREOF | LEXICON PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| WO-2023167806-A1 | METHODS AND COMPOUNDS USEFUL IN THE SYTHESIS OF AN AAK1 INHIBITOR | LEXICON PHARMACEUTICALS, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023167806-A1 | METHODS AND COMPOUNDS USEFUL IN THE SYTHESIS OF AN AAK1 INHIBITOR | LEXICON PHARMACEUTICALS, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023167807-A1 | SOLID FORMS OF (S)-L-((2',6-BIS(DIFLUOROMETHYL)-[2,4'-BIPYRIDIN]-5-YL)OXY)-2,4-DIMETHYLPENTAN-2-AMINE AND SALTS THEREOF | LEXICON PHARMACEUTICALS, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023167807-A1 | SOLID FORMS OF (S)-L-((2',6-BIS(DIFLUOROMETHYL)-[2,4'-BIPYRIDIN]-5-YL)OXY)-2,4-DIMETHYLPENTAN-2-AMINE AND SALTS THEREOF | LEXICON PHARMACEUTICALS, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12344596-B2 | Solid forms of (S)-1-((2′,6-bis(difluoromethyl)-[2,4′-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine and salts thereof | AAK1, SIK1, SBK1 | KMO 642/4885MAP4K4 155/4885MINK1 10/4885 |
| US-20250282747-A1 | METHODS AND COMPOUNDS USEFUL IN THE SYNTHESIS OF AN AAK1 INHIBITOR | AAK1, NEK1, SIK1 | KMO 660/4885MAP4K4 124/4885MINK1 49/4885 |
| US-12312325-B2 | Methods and compounds useful in the synthesis of an AAK1 inhibitor | AAK1, NEK1, SIK1 | KMO 660/4885MAP4K4 124/4885MINK1 49/4885 |
| US-20230357182-A1 | SOLID FORMS OF (S)-1-((2',6-BIS(DIFLUOROMETHYL)-[2,4'-BIPYRIDIN]-5-YL)OXY)-2,4-DIMETHYLPENTAN-2-AMINE AND SALTS THEREOF | AAK1, SIK1, SBK1 | KMO 645/4885MAP4K4 154/4885MINK1 10/4885 |
| US-20230357181-A1 | METHODS AND COMPOUNDS USEFUL IN THE SYTHESIS OF AN AAK1 INHIBITOR | AAK1, SIK1, NEK11 | KMO 1041/4885MAP4K4 206/4885MINK1 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.